Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AF Janus-associated kinase (JAK) inhibitors
L04AF07 Deucravacitinib
D11817 Deucravacitinib (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Immunological Agents
Immunological Agents, Other
Tyrosine Kinase 2 Inhibitor
Deucravacitinib
D11817 Deucravacitinib (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D11817 Deucravacitinib (JAN/USAN)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
D11817 Deucravacitinib
DG02919 CYP2B6 substrate
D11817 Deucravacitinib
DG01644 CYP2D6 substrate
D11817 Deucravacitinib
DG02970 CES substrate
DG03192 CES2 substrate
D11817 Deucravacitinib
DG02924 UGT substrate
DG03188 UGT1A9 substrate
D11817 Deucravacitinib
Target-based classification of drugs [BR:br08310]
Protein kinases
Non-receptor tyrosine kinases
JAK family
TYK2
D11817 Deucravacitinib (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11817
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11817
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11817
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11817
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11817